openPR Logo
Press release

Generic Drug Market Valued at USD 431.15 Billion in 2023: Poised for Robust Growth by 2030

01-16-2025 04:20 AM CET | Health & Medicine

Press release from: STELLAR MARKET RESEARCH

Generic Drug Market

Generic Drug Market

The ๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐ƒ๐ซ๐ฎ๐  ๐Œ๐š๐ซ๐ค๐ž๐ญ was valued at USD 431.15 billion in 2023 and is projected to grow at a CAGR of 5.22% during the forecast period, reaching nearly USD 615.72 billion by 2030.

๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐ƒ๐ซ๐ฎ๐  ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐Ž๐ฏ๐ž๐ซ๐ฏ๐ข๐ž๐ฐ:

Generic drugs are designed to be bioequivalent to branded medications, offering identical therapeutic effects, quality, and safety at a significantly reduced cost-typically 80-85% less than brand-name drugs. These drugs are extensively utilized in treating chronic diseases, ensuring affordability and accessibility for patients globally. The market's growth is fueled by patent expirations of branded drugs, increasing prevalence of chronic diseases, and rising demand for cost-effective healthcare solutions. Regions like North America and Asia-Pacific, led by countries such as the U.S., India, and China, dominate the market due to robust healthcare infrastructure and generic drug production capabilities.

๐–๐š๐ง๐ญ ๐ญ๐จ ๐’๐ž๐ž ๐ญ๐ก๐ž ๐“๐ซ๐ž๐ง๐๐ฌ? ๐‘๐ž๐ช๐ฎ๐ž๐ฌ๐ญ ๐š ๐…๐ซ๐ž๐ž ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐“๐จ๐๐š๐ฒ:https://www.stellarmr.com/report/req_sample/Generic-Drug-Market/1638

๐ƒ๐ซ๐ข๐ฏ๐ž๐ซ๐ฌ ๐ข๐ง ๐ญ๐ก๐ž ๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐ƒ๐ซ๐ฎ๐  ๐Œ๐š๐ซ๐ค๐ž๐ญ:

The market is driven by the rising prevalence of chronic diseases, such as diabetes and cardiovascular conditions, which necessitate affordable treatment options. The cost-effectiveness of generic drugs compared to branded counterparts makes them attractive to patients and healthcare providers. Additionally, government initiatives, such as the U.S. Drug Competition Action Plan (DCAP) and India's self-reliance policies for APIs, encourage generic drug adoption. Expiring patents of high-demand branded drugs further contribute to the growth of generics, providing patients with more affordable alternatives.

๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐ƒ๐ซ๐ฎ๐  ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐“๐ซ๐ž๐ง๐๐ฌ:

Emerging trends include the rise of super generics and biosimilars, offering enhanced formulations or delivery methods. Increasing adoption of robotic process automation (RPA) in drug manufacturing enhances efficiency and reduces costs. Regulatory efforts, such as the Patient Protection and Affordable Care Act (ACA) in the U.S., are facilitating easier market entry for generics while maintaining quality standards. In addition, expanding online pharmacy channels and growing consumer awareness about generic drug benefits are shaping the future trajectory of the market.

๐“๐ก๐ž ๐ˆ๐ง๐ญ๐ž๐ซ๐ž๐ฌ๐ญ๐ž๐ ๐’๐ญ๐š๐ค๐ž๐ก๐จ๐ฅ๐๐ž๐ซ๐ฌ ๐œ๐š๐ง ๐ˆ๐ง๐ช๐ฎ๐ข๐ซ๐ž ๐Ÿ๐จ๐ซ ๐ญ๐ก๐ž ๐๐ฎ๐ซ๐œ๐ก๐š๐ฌ๐ž ๐จ๐Ÿ ๐ญ๐ก๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ:https://www.stellarmr.com/report/enquire_now/Generic-Drug-Market/1638

๐Œ๐ž๐ซ๐ ๐ž๐ซ๐ฌ ๐š๐ง๐ ๐€๐œ๐ช๐ฎ๐ข๐ฌ๐ข๐ญ๐ข๐จ๐ง๐ฌ ๐ข๐ง ๐ญ๐ก๐ž ๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐ƒ๐ซ๐ฎ๐  ๐Œ๐š๐ซ๐ค๐ž๐ญ: ๐†๐ฅ๐จ๐›๐š๐ฅ ๐”๐ฉ๐๐š๐ญ๐ž๐ฌ

๐†๐ซ๐จ๐ฐ๐ญ๐ก ๐Ž๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐ž๐ฌ ๐ข๐ง ๐•๐ข๐ž๐ญ๐ง๐š๐ฆ

Vietnam's generic drug market is expanding rapidly, fueled by government initiatives to increase the availability of affordable medicines. The market grew by 8% in 2023, driven by rising healthcare infrastructure and demand for essential medicines. Companies like Sanofi and Novartis are forming partnerships with local pharmaceutical firms to enhance distribution and production capabilities.

๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐ƒ๐ซ๐ฎ๐  ๐“๐ซ๐ž๐ง๐๐ฌ ๐ข๐ง ๐“๐ก๐š๐ข๐ฅ๐š๐ง๐

Thailand's focus on universal healthcare and access to affordable medications has boosted the generic drug market. The market witnessed a 7.5% year-on-year growth in 2023, with high demand for antibiotics and cardiovascular drugs. Leading companies such as Teva Pharmaceuticals and Pfizer are collaborating with Thai health agencies to introduce high-quality generics in the market.

๐Ž๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐ž๐ฌ ๐ข๐ง ๐‰๐š๐ฉ๐š๐ง'๐ฌ ๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐ƒ๐ซ๐ฎ๐  ๐Œ๐š๐ซ๐ค๐ž๐ญ

Japan's generic drug market is driven by the government's push to reduce healthcare costs. In 2023, generics accounted for 80% of all prescriptions, and the market grew by 6.2%. Companies like Takeda Pharmaceutical and Astellas Pharma are leading the market with innovative formulations that meet Japan's stringent regulatory standards.

๐’๐จ๐ฎ๐ญ๐ก ๐Š๐จ๐ซ๐ž๐š'๐ฌ ๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐ƒ๐ซ๐ฎ๐  ๐†๐ซ๐จ๐ฐ๐ญ๐ก

South Korea's strong pharmaceutical manufacturing sector is driving growth in the generic drug market. The market expanded by 6.8% in 2023, with rising demand for biosimilars and oncology drugs. Local players like Celltrion and Hanmi Pharmaceutical are investing heavily in R&D to develop high-quality generics that cater to global markets.

๐“๐ซ๐ž๐ง๐๐ฌ ๐ข๐ง ๐’๐ข๐ง๐ ๐š๐ฉ๐จ๐ซ๐ž'๐ฌ ๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐ƒ๐ซ๐ฎ๐  ๐ˆ๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ

Singapore's position as a regional healthcare hub is fostering growth in its generic drug market. The market recorded an 8.2% growth in 2023, supported by government incentives for generics and biosimilars. Companies such as Mylan and Sandoz are collaborating with local distributors to cater to the growing demand for cost-effective medicines in Singapore.

๐†๐ซ๐จ๐ฐ๐ญ๐ก ๐ข๐ง ๐ญ๐ก๐ž ๐”๐’ ๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐ƒ๐ซ๐ฎ๐  ๐Œ๐š๐ซ๐ค๐ž๐ญ

The United States leads the global generic drug market, accounting for over 40% of global revenue in 2023. The growth is driven by the expiration of patents for major drugs and the rising prevalence of chronic diseases. Key players like Teva Pharmaceuticals, Sandoz, and Mylan are introducing innovative generics and biosimilars to meet the country's growing demand.

๐Ž๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐ž๐ฌ ๐ข๐ง ๐„๐ฎ๐ซ๐จ๐ฉ๐ž'๐ฌ ๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐ƒ๐ซ๐ฎ๐  ๐Œ๐š๐ซ๐ค๐ž๐ญ

Europe's generic drug market is growing steadily, with countries like Germany, the UK, and France leading in adoption. The market grew by 6.5% in 2023, driven by government policies encouraging generic usage to reduce healthcare costs. Companies such as Fresenius Kabi and Hikma Pharmaceuticals are investing in advanced manufacturing technologies to enhance production efficiency.

๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐…๐ฎ๐ฅ๐ฅ ๐๐ƒ๐… ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‚๐จ๐ฉ๐ฒ ๐จ๐Ÿ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ @https://www.stellarmr.com/report/req_sample/Generic-Drug-Market/1638

๐’๐ž๐ ๐ฆ๐ž๐ง๐ญ๐š๐ญ๐ข๐จ๐ง ๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐จ๐Ÿ ๐ญ๐ก๐ž ๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐ƒ๐ซ๐ฎ๐  ๐Œ๐š๐ซ๐ค๐ž๐ญ:

By Type

Simple Generics
Super Generics
Biosimilars

By Brand

Pure Generics
Branded Generics

By End-User

Hospitals
Homecare
Speciality Clinics
Others

๐…๐จ๐ซ ๐ฆ๐จ๐ซ๐ž ๐ข๐ง๐Ÿ๐จ๐ซ๐ฆ๐š๐ญ๐ข๐จ๐ง ๐š๐›๐จ๐ฎ๐ญ ๐ญ๐ก๐ข๐ฌ ๐ซ๐ž๐ฉ๐จ๐ซ๐ญ ๐ฏ๐ข๐ฌ๐ข๐ญ:https://www.stellarmr.com/report/Generic-Drug-Market/1638

๐–๐ก๐จ ๐ข๐ฌ ๐ญ๐ก๐ž ๐ฅ๐š๐ซ๐ ๐ž๐ฌ๐ญ ๐ฆ๐š๐ง๐ฎ๐Ÿ๐š๐œ๐ญ๐ฎ๐ซ๐ž๐ซ๐ฌ ๐จ๐Ÿ ๐†๐ž๐ง๐ž๐ซ๐ข๐œ ๐ƒ๐ซ๐ฎ๐  ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐ฐ๐จ๐ซ๐ฅ๐๐ฐ๐ข๐๐ž?

Teva Pharmaceutical Industries Ltd.
Novartis AG (Sandoz International)
Viatris
Sun Pharma
Fresenius Kabi
Aurobindo Pharma
Mylan N.V.
Pfizer Inc.
Sanofi
Novel Understanding
Fresenius SE & Co.
Lupin Limited
Endo Pharmaceuticals Inc.
Aspen Pharmacare Holdings Limited
Dr. Reddy's Laboratories
Glenmark Pharmaceuticals
Cipla Ltd.
Alkem Laboratories
Cadila Healthcare Ltd.
Intas Pharmaceuticals Ltd.

๐„๐ฑ๐ฉ๐ฅ๐จ๐ซ๐ž ๐‘๐ž๐ฅ๐š๐ญ๐ž๐ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ๐ฌ ๐›๐ฒ ๐’๐ญ๐ž๐ฅ๐ฅ๐š๐ซ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก:

โ™ฆBike Sharing Market https://www.stellarmr.com/report/Bike-Sharing-Market/44

โ™ฆMembrane Market https://www.stellarmr.com/report/Membrane-Market/112

โ™ฆBanking-as-a-Service (BaaS) Market https://www.stellarmr.com/report/Banking-as-a-Service--BaaS--Market/121

โ™ฆAir Purifier Market https://www.stellarmr.com/report/Air-Purifier-Market/122

โ™ฆFormalin Market https://www.stellarmr.com/report/Formalin-Market/127

โ™ฆComposite Filling Market https://www.stellarmr.com/report/Composite-Filling-Market/128

๐‚๐จ๐ง๐ญ๐š๐œ๐ญ ๐’๐ญ๐ž๐ฅ๐ฅ๐š๐ซ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก:
S.no.8, h.no. 4-8 Pl.7/4, Kothrud,
Pinnac Memories Fl. No. 3, Kothrud, Pune,
Pune, Maharashtra, 411029
sales@stellarmr.com

๐€๐›๐จ๐ฎ๐ญ ๐’๐ญ๐ž๐ฅ๐ฅ๐š๐ซ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก:

Stellar Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include science and engineering, electronic components, industrial equipment, technology, and communication, cars, and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Generic Drug Market Valued at USD 431.15 Billion in 2023: Poised for Robust Growth by 2030 here

News-ID: 3816959 • Views: โ€ฆ

More Releases from STELLAR MARKET RESEARCH

Ready to Eat (RTE) Baked Products and Bakery Premixes Market Share, Industry Growth, Business Strategy, Trends and Regional Outlook 2032
Ready to Eat (RTE) Baked Products and Bakery Premixes Market Share, Industry Gro โ€ฆ
Ready to Eat (RTE) Baked Products and Bakery Premixes Market was estimated at USD 154.85 Bn. in 2024 and the total revenue is projected to grow at CAGR of 7% From 2025 to 2032 reaching nearly USD 231.41 Bn. by 2032. Stellar Market Research published a report "Ready to Eat Baked Products and Bakery Premixes Market and forecast (2025-2032)." The report is a comprehensive analysis of global Ready to Eat Bakedโ€ฆ
Micromotor Market Comprehensive Research Study, Competitive Landscape and Forecast 2025-2032
Micromotor Market Comprehensive Research Study, Competitive Landscape and Foreca โ€ฆ
Micromotor Market was estimated at USD 43.10 Bn in 2024, and its total revenue is projected to grow at a CAGR of 7.1% from 2025 to 2032, reaching nearly USD 69.66 Bn by 2032. Stellar Market Research published a report "Micromotor Market and forecast (2025-2032)." The report is a comprehensive analysis of global Micromotor Market share, size, growth, trends, and forecast. The report also contains competitor analysis and regional analysis andโ€ฆ
Monkeypox Vaccine and Treatment Market Sales and Revenues of Manufacturers Forecast till 2025-2032
Monkeypox Vaccine and Treatment Market Sales and Revenues of Manufacturers Forec โ€ฆ
Monkeypox Vaccine and Treatment Market size was estimated at USD 103.5 Mn in 2024 and the total Global Monkeypox Vaccine and Treatment revenue is projected to grow at a CAGR of 10.20% from 2025 to 2032, reaching nearly USD 225.12 Mn by 2032. Stellar Market Research published a report "Monkey pox Vaccine and Treatment Market and forecast (2025-2032)." The report is a comprehensive analysis of global monkey pox Vaccine and Treatmentโ€ฆ
K12 Education Market Dynamics, Competitive Landscape, Outlook 2025-2032
K12 Education Market Dynamics, Competitive Landscape, Outlook 2025-2032
K12 Education Market Size was valued at USD 2.65 Tn in 2024 and is projected to grow at a CAGR of 12.6% from 2025 to 2032, reaching nearly USD 6.85 Tn by 2032. Stellar Market Research has released a report "K12 Education Market and forecast (2025-2032)." The report is a detailed analysis of the global market share, size, growth, trends, and forecast of K12 Education Market. It also includes competitor andโ€ฆ

All 5 Releases


More Releases for Generic

Prominent Generic Oncology Drugs Market Trend for 2025: Novel Formulations Trans โ€ฆ
Which drivers are expected to have the greatest impact on the over the generic oncology drugs market's growth? The upward trend in cancer incidence is predicted to fuel the expansion of the generic oncology drugs market. Cancer, characterized by unregulated cell proliferation affecting numerous organs, results in considerable morbidity and mortality globally. The provision of affordable generic oncology drugs is an instrumental factor in cancer care, expanding access to vital treatments,โ€ฆ
Generic Theater Presents Flyin' West
NORFOLK, VA (August 2023) - Generic Theater inaugurates its 43rd season with Flyin' West, written by award-winning playwright and New York Times bestselling author Pearl Cleage. Terrance Afer-Anderson directs this production, running weekends September 8th - October 1st at Generic Theater, Norfolk's underground theater located in the basement of Chrysler Hall. Following the end of the Civil War, many former slaves took advantage of The Homestead Act and went West toโ€ฆ
Generic Injectables Market growth is attributed to the increasing demand for Onc โ€ฆ
According to Precision Business Insights (PBI), the latest report, the generic injectables market will be worth USD 22.0 billion in 2022, growing at an 11.0% CAGR from 2022 to 2028. The global generic injectables market is segmented into the following types: Product Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Immunoglobulins, Peptide Antibiotics, Vaccines, and Others), Indication (Diabetes, Cancer, Cardiovascular Diseases, Musculoskeletal, CNS, Infections, and Others), Distribution Channel (Hospitalโ€ฆ
A Demand On Generic Drugs Market And The Need To Push The Market Of Generic Drug โ€ฆ
Global Generic Drugs Market A generic drug is pharmaceutical drug, which is bio-equivalent to a branded drug in all forms such as route of administration, strength, dosage, quality, intended use and performance. Generic drugs are usually approved after patent expiration of patent drugs. Generic drugs are safe, effective and FDA approved. The global market is filled with 44% of generic drugs. The global generic drugs market is driven by the rise ofโ€ฆ
Generic Drug Market: Global Generic Drug Share to Reach USD 380.60 Billion by 20 โ€ฆ
Zion Market Research has published a new report titled โ€œGeneric Drug Market by Brand (Pure Generic and Branded Generic) for Central Nervous System (CNS), Cardiovascular, Dermatology, Oncology, Respiratory and Others Therapeutic Applications - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 โ€“ 2021โ€. According to the report, the global generic drug market accounted for around USD 200.20 billion in 2015 and is expected to reach approximately USD 380.60 billion byโ€ฆ
Generic Drugs: Global Collaboration Opportunities
Collaboration is the key to growth With the recent economic turmoil affecting many markets around the world, the generic and branded sectors face similar problems. At one time the generic sector was seen as a valuable way to bring effective products to a wider audience. This, allied to the rising cost of new advanced branded products, led to rapid expansion of the generics sector. Even markets traditionally based in the provision ofโ€ฆ